Abstract：OBJECTIVE: To observe the therapeutic effect of continuous blood purification (CBP) combined with hemoperfusion (HP) in children with hemolytic-uremic syndrome (HUS) and to investigate its possible mechanism. METHODS: Eight children with HUS received CBP combined with HP on the basis of internal medicine treatment in the acute stage. Before and after treatment, serum levels of interleukin-6 (IL-6), IL-8 and tumor necrosis factor-α (TNF-α) were measured by chemiluminescence method, and levels of blood urea nitrogen (BUN), serum creatinine (SCr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), creatine kinase MB (CKMB), hemoglobin (Hb), platelet (PLT) and C-reactive protein (CRP) were measured. Eight healthy children undergoing physical examination were used as controls. RESULTS: The 8 children with HUS all survived after CBP combined with HP and showed improved conditions. They had increased Hb and PLT levels and decreased serum levels of IL-6, IL-8, TNF-α, BUN, SCr, ALT, CK and CRP after treatment (P<0.05). CONCLUSIONS: CBP combined with HP can quickly remove pathogenic factors, continually eliminate inflammatory mediators and toxins, and reverse multiple organ dysfunction, and is one of effective methods for treating HUS in children.
ZHU Ying,DONG Yang,XU Da-Liang et al. Application of continuous blood purification combined with hemoperfusion in the treatment of hemolytic-uremic syndrome in children[J]. CJCP, 2013, 15(1): 53-55.
［2］Santiago MJ, López-Herce J, Urbano J, Solana MJ, del Castillo J, Ballestero Y, et al.Clinical course and mortality risk factors in critically ill children requiring continuous renal replacement therapy［J］. Intensive Care Med, 2010, 36(5): 843-849.
［2］Santiago MJ, López-Herce J, Urbano J, Solana MJ, del Castillo J, Ballestero Y, et al.Clinical course and mortality risk factors in critically ill children requiring continuous renal replacement therapy［J］. Intensive Care Med, 2010, 36(5): 843-849.
［7］Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP.Advances in understanding of pathogenesis of aHUS and HELLP［J］. Br J Haematol, 2008, 143(3): 336-348.
［8］Provaznikova D, Rittich S, Malina M, Seeman T, Marinov I, Riedl M, et al. Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP［J］. Pediatr Nephrol, 2012, 27(1): 73-81.
［5］Stahl AL, Sartz L, Karpman D.Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytid uremic syndrome［J］. Blood, 2011, 117(20): 5503-5513.
［9］Johnson S, Waters A.Is complements a culprit in infection-induced forms of haemolytic uraemic syndrome?［J］. Immunobiology, 2011, 26. ［Epub ahead of print］.
［7］Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP.Advances in understanding of pathogenesis of aHUS and HELLP［J］. Br J Haematol, 2008, 143(3): 336-348.
［11］Chen ZH, Liu ZH, Yu C, Ji DX, Li LS.Endothelial dysfunction in patients with severe acute pancreatitis:improved by continuous blood purification therapy［J］.Int J Artif organs, 2007, 30(5): 393-400.
［8］Provaznikova D, Rittich S, Malina M, Seeman T, Marinov I, Riedl M, et al. Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP［J］. Pediatr Nephrol, 2012, 27(1): 73-81.
［9］Johnson S, Waters A.Is complements a culprit in infection-induced forms of haemolytic uraemic syndrome?［J］. Immunobiology, 2011, 26. ［Epub ahead of print］.
［11］Chen ZH, Liu ZH, Yu C, Ji DX, Li LS.Endothelial dysfunction in patients with severe acute pancreatitis:improved by continuous blood purification therapy［J］.Int J Artif organs, 2007, 30(5): 393-400.
